BioSpace News Archive

Valo Therapeutics Oy announces it is the first biotech company in Europe to install and use the Bruker Corporation’s new timsTOF Ultra mass spectrometer and liquid chromatography platform, which provides transformative speed and sensitivity for antigen identification in connection with ValoTx’s PeptiCHIP technology.

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc.

Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is proud to recognize the fourth Hereditary Factor X Deficiency Awareness Day on October 10, 2023.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company’s path to profitability.

Ocugen, Inc. announced that the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, will conduct a trial comparing the administration of Ocugen’s mucosal vaccine candidate, OCU500, via two different mucosal routes, inhalation into the lungs and as a nasal spray.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis.

Annexon, Inc. announced that the European Medicines Agency granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome.

Merck, known as MSD outside of the United States and Canada, announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer met its dual primary endpoint of overall survival.

Medicenna Therapeutics Corp. announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer to lead the development strategy and execution of Medicenna’s clinical programs.

Molecular Designs, a developer and manufacturer of molecular infectious disease assays, announces the release of its new Direct-PCR Covid/Flu/RSV Simplicity Panel™.